GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
116 articles in GLP-1 & Metabolic · page 7 of 10
GLP-1s and Eating Disorders: A Cautious Look
Appetite-suppressing drugs demand particular care here. What the limited eating-disorder evidence shows, and where the real risks sit.
Read →Why GLP-1 Trials Use Different Endpoints
Weight, A1c, cardiovascular events: what a GLP-1 trial measures shapes what its result can honestly claim. How to read the choice.
Read →GLP-1s in Adolescents: The Evidence and the Debate
In STEP TEENS, semaglutide cut BMI about 16% over 68 weeks. Efficacy is clear; long-term safety in growing bodies is not.
Read →The Durability Question: GLP-1s as Chronic Therapy
These look more like blood-pressure drugs than a course of antibiotics. Why that framing matters for how long people stay on them.
Read →Amylin and the Next Wave: CagriSema, Explained
CagriSema cut weight about 20% in REDEFINE 1 (NEJM 2025). The amylin-plus-GLP-1 strategy in context, and what is still unapproved.
Read →GLP-1s and Blood Pressure: What the Trials Found
GLP-1 drugs show a modest but consistent blood-pressure effect that adds to the cardiometabolic case. What the trials measured, and how much.
Read →GLP-1s and Cholesterol: Secondary Metabolic Effects
Weight is not the only marker that moves on a GLP-1. What the lipid data from the semaglutide trials shows, and how much is weight loss.
Read →Survodutide and the GLP-1/Glucagon Approach
A GLP-1/glucagon dual agonist with phase 2 MASH and obesity data. What is verified, what is not, and how it differs from GLP-1s.
Read →GLP-1 Shortages: What Drove Them and What's Next
Demand outran supply for years. What caused it, when the FDA called it resolved, and what that then changed for compounding.
Read →GLP-1s and the Gut Microbiome
A 2025 review found 38 studies but only 9 in humans, with inconsistent diversity results. The thread is real; conclusions aren't.
Read →Generic GLP-1s: When Will Prices Fall?
Generic liraglutide arrived in 2024-2025; semaglutide and tirzepatide are protected far longer. The real price timeline.
Read →Protein Intake on a GLP-1: Why It Matters More
DEXA data shows ~40% of GLP-1 weight loss can be lean mass. Why protein and resistance training matter more when appetite drops.
Read →